NCT04007198 - A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions

Asthma

Interventions

DRUG

EQ001

Itolizumab \[Bmab 600\]

DRUG

EQ001 Placebo

Trial Locations (13)

Flinders Medical Centre, Adelaide

Box Hill Hospital, Box Hill

Monash Medical Centre, Clayton

Paratus Clinical Research Central Coast, Kanwal

Respiratory Clinical Trials, Kent Town

TrialsWest, Murdoch

Melbourne Health, Parkville

Paratus Clinical Research Western Sydney, Sydney

The Queen Elizabeth Hospital, Woodville

Respiratory Research, Greenland Clinical Centre, Auckland

Dunedin Hospital, Dunedin

The New Zealand Respiratory & Sleep Institute, Greenlane

Medical Research Institute of New Zealand, Wellington